Dogs suffering from separation anxiety are often "owner addicts." While treatment and management options are available for dogs suffering from separation anxiety, there is no instant cure. However, the disorder can dissipate on its own if the trigger stimulus is removed from its environment or the trigger stimulus is desensitized over a period. The canine may not suffer from separation anxiety on a long-term basis if training, consistent routines, lifestyle changes, or medication is in place. A better
prognosis is achieved by providing treatment.
Drug therapy Dogs can be treated with psychotropic drugs used to treat similar psychological disorders displayed in humans in order to mitigate the behavior related to these disorders, such as anti-depressants or anti-anxiety drugs. These connections between human and animal psychopharmacology can help to explain how similar neurobiology can be among different species.
Selective Serotonin Reuptake Inhibitors, or SSRIs, or tricyclic anti-depressants are used to treat anxious and depressive behavior in animals. One study tracked the effectiveness of
clomipramine, a tricyclic anti-depressant, in reducing compulsive behaviors in dogs. Behaviors displayed by these dogs include but are not limited to
tail-chasing, shadow-chasing, circling and chewing. The study found that after one month of daily administration of the tricyclic anti-depressant clomipramine, these compulsive behaviors decreased or disappeared in 16 out of 24 dogs. Slight to moderate behavior mitigation was shown in 5 dogs. These results suggest that clomipramine can be beneficial to canines displaying anxiety behaviors.
Anti-depressant treatment Fluoxetine, an
SSRI used by humans under the brand name Prozac, is prescribed to dogs under the brand name Reconcile. A study found that dogs who were being simultaneously treated with Reconcile while undergoing a type of
behavior therapy known as behavioral modulation were more successful at mitigating behaviors related to separation anxiety when compared to the
control group of dogs receiving only a
placebo with behavior modulation treatment. After 8 weeks of treatment, 72% of the dogs given fluoxetine displayed fewer adverse behaviors (e.g., excessive salivation, inappropriate urination/defecation) while only 50% of the control group mitigated these behaviors. In another study conducted in 2015, dogs expressing symptoms of separation anxiety were given fluoxetine tablets and a standard
behavior modification plan for two months. Owner interviews, spatial
cognitive bias tests, questionnaires and relations between cognitive bias and drug treatment were all taken into consideration. Results showed that the clinical treatment of fluoxetine seemed to produce a shift in cognitive bias in the canine subjects, emphasizing that
pharmacological therapy not only can positively affect behavior, but also an animal's psychological state. The most common adverse effects were decreased appetite, experienced by 23% of the dogs in the study, and lethargy, experienced by 39% of the dogs in the study. Some canines actually experienced worsening anxiety and aggressive behavior. In a study using the anti-depressant
clomipramine, nine dogs underwent withdrawal after discontinuing treatment. Five of those dogs were successful in overcoming the withdrawal, while four dogs relapsed. Although the study's sample sizes were relatively small, it illuminated one of the many variables regarding psychoactive
drug withdrawal.
Benzodiazepine treatment Benzodiazepines, such as alprazolam, are
anxiolytic medications. Benzodiazepines are beneficial in the treatment of stimuli-evoking anxiety, or
phobias. One study on storm phobias found that 30 out of the 32 canines involved in the study had reductions in anxious behaviors after being treated with alprazolam. However, this study found that the best way to benefit from benzodiazepine treatment is when it is being used in conjunction with behavior modulation treatment and an anti-depressant. The study found that canines can develop dependence to these types of medications and experience a withdrawal process similar to one experienced by humans. For example, their seizure threshold is lowered and anxiety relapse can occur after stopping benzodiazepine treatment. Similarly to treatment of human anxiety disorders, benzodiazepines are a last resort treatment, due to their addiction potential.
Selective Serotonin Reuptake Inhibitors, or SSRIs, or tricyclic anti-depressants are used to treat anxious and depressive behavior in animals. One study tracked the effectiveness of
clomipramine, a tricyclic anti-depressant, in reducing compulsive behaviors in dogs. Behaviors displayed by these dogs include but are not limited to
tail-chasing, shadow-chasing, circling and chewing. The study found that after one month of daily administration of the tricyclic anti-depressant clomipramine, these compulsive behaviors decreased or disappeared in 16 out of 24 dogs. Slight to moderate behavior mitigation was shown in 5 dogs. These results suggest that clomipramine can be beneficial to canines displaying anxiety behaviors. Because imepitoin is known to have anti-convulsant effects on laboratory rats and is already an anti-epilepsy drug treatment, researchers are curious as to whether or not it could decrease a canine's levels of separation anxiety, as one symptom of separation anxiety in dogs is excessive shaking, primarily in smaller breeds. One study conducted in 2016 did not test its effects on separation anxiety specifically, but rather investigated its abilities to reduce fear and anxiety-related behaviors. The study was conducted via an online survey completed by the canine participants' owners, including data on the number of how monthly seizures the dogs experienced. Results showed a significant reduction of average seizures per month, but no significant differences in behavior regarding the five anxiety-related measures examined (dog-directed fear, stranger-directed fear, non-social fear, pain sensitivity and separation-related behavior), concluding that imepitoin did not definitively affect anxiety-related behavior in dogs. However, it was noted by researchers conducting the study that the participants' anxiety levels could not have been high enough in the beginning of the study for the dogs to show a significant reduction in anxiety-related behavior. Another research study in June 2017 tested imepitoin's abilities to reduce anxiety-related behaviors in canines, but unlike the previous study, researchers evaluated the dogs personally for canine temperament using a Positive and Negative Activation Scale (PANAS), rather than having the participants' owners evaluate the dogs through an online survey. Average weekly reaction (AWR) scores in response to anxiety-inducing stimuli and owners' diary entries were also taken into account. Results displayed significantly lower AWR scores for anxiety alongside a reduction in negative activation on the PANAS, concluding that imepitoin is a drug-therapy option to positively reduce canines' anxiety-related behaviors. However, imepitoin is not being prescribed to treat separation anxiety in canines.
Environmental management Managing and controlling the canine environment is one method used to help treat separation anxiety in dogs. The focus is to reduce the canine's anxiety while eliminating possible means of self-injury or harm to the surrounding environment. In the cases of some dogs, crate training can provide an effective enclosure in which the canine feels safe and comfortable, whilst eliminating possible means of harm in the environment, as they are enclosed. The use of a crate or small, enclosed structure is effective for dogs who have been accustomed to
crate training before, however introducing this method past the accustomed age of house training, can worsen the symptoms experienced by the dog. Self-harm and injury to the animal can also increase as confinement can cause distress leading to the canine trying to escape. Another method used to reduce distress in dogs experiencing separation anxiety is the use of a dog-appeasing pheromone. Studies proved that 83 percent of dogs exposed to a pheromone, in the absence of their owner, experienced reduced stress and anxiety; 70% of dogs prescribed clomipramine, a psychotropic drug, experienced said reduction in separation-induced symptoms. The
dog-appeasing pheromone (DAP), also known as apasine, is a pheromone secreted by lactating females by the sebaceous glands in the intermammary sulcus. Young and adult canines detect the pheromone through the Jacobson's organ or vomero-nasal organ (VNO), and in result, detection ameliorates symptoms related to separation anxiety, phobias, and hyper-attachment. Synthetic forms of dog-appeasing pheromone, such as Adaptil, have been developed by the pharmaceutical industry for over-the-counter use, however their efficacy is reduced in comparison to natural DAP. As the stimulus, absence of owner and behavioural responses relating to separation anxiety are present, exposure to small intervals of owners' absence can condition the behavioural responses to change and become calm and positive. Absence period is gradually extended up to a suitable period of time of which anxiety-induced behavioural responses no longer occur.
Behavioural management Behavioural management consists of several non-medication type treatments that reduce the effects of separation anxiety on the dog and homeowners. A behavioural technique found to aid in management of the disorder is to cease all forms of punishment related to the animals behaviour. Punishment in cases of separation anxiety does not reduce the behaviour or anxiety levels of dogs; it increases their stress levels, prolonging the symptoms and behavioural responses induced by separation. Systematic desensitization is a technique used to reduce anxiety-induced behavioural responses; is based on
classical conditioning. As the stimulus, absence of owner and behavioural responses relating to separation anxiety are present, exposure to small intervals of owners' absence can condition the behavioural responses to change and become calm and positive. Absence period is gradually extended up to a suitable period of time of which anxiety-induced behavioural responses no longer occur. By repeatedly demonstrating short owner absence times, non-anxious behaviour over longer absence times is eventually encouraged. The main goal of this step is to extend absence time where the canine does not experience separation-related behaviour problems; reducing anxiety for the dog and homeowner. It is important that the canine does not experience a traumatic event during this training, otherwise desensitization will not be successful.
Counterconditioning is also used in conjunction with systematic desensitization; the intent to change an animal's emotional response to a stimulus. Counterconditioning is achieved by pairing the stimulus that elicits the negative response with a stimulus that elicits a positive response, thus changing the emotional response from fear and anxiety to calm and positive. The canine is conditioned to associate the fearful stimuli with a positive outcome (e.g., given toy or food during departure of owner). Treatment had a greater success rate when systematic desensitization and counterconditioning were paired; canines treated by Rogerson with systematic desensitization and counterconditioning for anxiety-related behavioural responses had a 100% success rate. When leaving the house, or while still within the household, but out of sight, an important strategy to employ is to ignore clingy or attention-seeking behavior. Responding to canines' attention-seeking behaviours can also be related to
operant conditioning; positively reinforcing the behaviour increases the likelihood of the behavioural response to re-occur, however the use of negative punishment (i.e., not acknowledging behaviour) will reduce attention-seeking behavioural responses, which reduces the dog's dependency on the owner. == Research ==